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Paclitaxel and oxaliplatin are promising drugs for combination trials but both induce peripheral neurotoxicity. To investigate this
toxicity, 10-week-old female Wistar rats were given single intraperitoneal doses of paclitaxel and oxaliplatin, alone or in combination.
Neurotoxicity was assessed by L5 dorsal root ganglion morphometry and H-reflex-related sensory nerve conduction velocity.
Platinum concentrations in dorsal root ganglia and plasma were measured by inductively coupled plasma mass spectrometry. Dorsal
root ganglion nucleolus size was significantly increased following single doses of paclitaxel of 10 and 20mgkg
 1 at 24h and 6 days
(Po0.02). In contrast, dorsal root ganglion nucleolus size was significantly decreased following single doses of oxaliplatin ranging from
3t o3 0m gk g
 1 at time points ranging from 2h to 14 days. Sensory nerve conduction velocity was altered after a single dose of
oxaliplatin but not after paclitaxel. In combination with oxaliplatin, paclitaxel did not alter the plasma pharmacokinetics or dorsal root
ganglion accumulation of oxaliplatin-derived platinum. However, prior paclitaxel inhibited oxaliplatin-induced reductions of dorsal
root ganglion nucleolar diameter (Po0.02). Sensory nerve conduction velocity was reduced after oxaliplatin alone (Po0.05) but
unchanged when paclitaxel was given before oxaliplatin. In conclusion, paclitaxel induces nucleolar enlargement in dorsal root
ganglion neurons after pharmacologically relevant doses in vivo and reduces oxaliplatin nucleolar damage and neurotoxicity.
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Peripheral sensory neurons are a heterogeneous group of postmitotic
cells (reviewed in Perl, 1992) that are damaged by chemotherapy
drugs. The cell bodies of peripheral sensory neurons are contained
within the dorsal root ganglia, and their axons extend for large
distances to innervate peripheral tissues and the central nervous
system. The cell bodies and peripherally directed axons of dorsal
root ganglion neurons lack the protection of the blood–brain
barrier, and are exposed to neurotoxins to a greater extent than the
central nervous system. For example, the dorsal root ganglion is the
main site of platinum accumulation during treatment with platinum-
based antitumour drugs (Gregg et al, 1992; Screnci et al, 2000).
Dorsal root ganglion neurons have a large nucleolus, evident as
a prominent dark-staining subnuclear structure by light micro-
scopy. The nucleolus is the cellular site of rDNA gene transcription
and processing of preribosomal RNA transcripts (Shaw and
Jordan, 1995). The prominence of the nucleolus of dorsal root
ganglion neurons presumably reflects a high requirement for
ribosomal gene transcription, ribosome production and protein
synthesis to maintain their large cell body and extensive axonal
projections. The neurotoxicity of platinum-based drugs has been
previously linked to damage to the nucleolus of dorsal root
ganglion neurons (Tomiwa et al, 1986; Muller et al, 1990; Cavaletti
et al, 1992, 1998; Cece et al, 1995; Stacchiotti et al, 1995; Holmes
et al, 1998). For example, we have previously shown that the
neurotoxicity of a series of platinum-based drugs correlates with
the rate of shrinkage of dorsal root ganglia nucleoli during
multiple-dose treatment (McKeage et al, 2001). Less is known
about the dorsal root ganglia nucleolar effects of paclitaxel, an
anticancer drug whose clinical application is also limited by
peripheral neuropathy.
Paclitaxel and oxaliplatin are showing promising activity given
in combination clinical trials in drug refractory ovarian cancer
(Faivre et al, 1999; Delaloge et al, 2000). Their mechanisms of
action involve the arrest of cell progression through the mitotic
cycle and cytotoxicity to proliferating tumour cells, respectively
(Raymond et al, 1998; Blagosklonny and Fojo, 1999). The clinical
application of this drug combination has been limited by
neurotoxicity possibly due to damage to dorsal root ganglion
neurons. This toxicity is not readily explained by their mechan-
isms of action since dorsal root ganglion neurons are postmitotic
cells and not susceptible to antiproliferative toxicity. With these
considerations, it seemed reasonable to investigate the effects of
paclitaxel on dorsal root ganglia in vivo, given alone and in
combination with oxaliplatin.
METHODS
Animals and treatment
Female Wistar rats (10-week-old, age-matched) were used that
weighed between 200 and 300g at the start of the experiments, and
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swere acclimatised to handling prior to drug treatment. Paclitaxel
(Phytogen Life Sciences Inc., Delta, BC, Canada) was prepared by
solubilisation in Cremophor EL (Sigma, St Louis, MO, USA)/
ethanol/0.9% NaCl (Baxter Healthcare, Old Toongabbie, Australia)
by vortexing and sonication at an injection volume of 10mlkg
 1
body weight. Oxaliplatin (Sanofi Winthrop, France) was dissolved
in 0.9% NaCl, vortexed and sonicated, and administered to the
animals at an injection volume of 10mlkg
 1. In each case, control
animals were administered the relevant drug vehicle alone. All
drug treatments were administered by intraperitoneal injection.
When the drugs were given in combination, paclitaxel was given
24h before oxaliplatin, and dorsal root ganglia parameters and
sensory nerve conduction velocity were measured at 24h and 3
weeks after dosing of oxaliplatin, respectively. All animal
procedures and use complied with ethical guidelines and were
approved by the Animal Ethics Committee of the University of
Auckland and met the requirements of the UKCCCR guidelines.
Animals were maintained in a constant environment and had
unrestricted access to food and water. Animals were checked daily
for signs of toxicity. Any animals suffering visible toxicity were
immediately euthanised.
Dorsal root ganglion morphometry
Animals were anaesthetised with 0.9ml of 3mgml
 1 pentobarbi-
tone (Chemstock Animal Health Ltd., Christchurch, New Zealand).
Following the induction of deep anaesthesia, intracardiac para-
formaldehyde perfusion was carried out by administering 60ml of
0.9% NaCl, followed by 60ml of 4% paraformaldehyde in 0.1 M
phosphate buffer. L5 dorsal root ganglia were carefully dissected
out and stored in 4% paraformaldehyde. Dorsal root ganglia were
washed in water, dehydrated in a series of alcohols, cleared in
xylene and embedded in paraffin wax. A microtome was then used
to cut each dorsal root ganglion into 6mm sections. Typically,
about 60–80 sections were produced for each dorsal root ganglion.
Sections were mounted on slides and stained with haematoxylin
and eosin. A total of 10 sections selected at random regular
intervals were analysed from each dorsal root ganglion by light
microscopy at  630 magnification. Images were digitally photo-
graphed to a computer by an Axiocam camera (Carl Zeiss Vision).
Area or perpendicular diameters were measured for the cell body,
nucleus and nucleolus of the two to five largest cells of each section
by AxioVision 3.0 (Carl Zeiss Software) software. Morphometric
parameters from the 10 largest dorsal root ganglion nerve cells
were averaged to provide the cell body, nucleus and nucleolus
measurements for each dorsal root ganglion.
Sensory nerve conduction velocity (SNCV) recordings
Recordings of evoked H-plantar responses following nerve
stimulation at the ankle and sciatic notch were used to calculate
SNCV as described previously (McKeage et al, 1994). Briefly,
animals were anaesthetised with intramuscular Hypnorm (Janssen
Pharmaceutica, Beerse, Belgium) diluted 1:1 in milli-Q water.
Percutaneous needle electrodes were used to generate responses by
electrically stimulating the sciatic nerve at the sciatic notch and the
tibial nerve at the ankle of the left hind limb. H- and M-waves were
recorded through differential silver/silver chloride electrodes fixed
to the sole and dorsum of the left hind leg. SNCV was calculated by
dividing the distance between the sites of stimulation by the
difference in evoked H-response latencies between the ankle and
sciatic notch after stimulation.
Plasma and tissue platinum determinations
At 0, 15, 30, 45min, 1, 2, 4 and 24h after the administration of
oxaliplatin, blood samples (approximately 100ml) were taken from
the tail artery of each animal into tubes containing heparin diluted
with 0.9% NaCl. Methanol extracts of plasma were prepared by
centrifugation of whole blood at 5000r.p.m. for 10min, followed
by addition of an equal volume of ice-cold methanol to plasma and
two further centrifugation steps at 14000r.p.m. for 15min. Plasma
samples were stored at  201C prior to analysis by inductively
coupled plasma mass spectrometry. On the day of analysis,
methanol extracts of plasma were diluted with 1% nitric acid to
give a volume of 2ml per sample. Samples were then analysed
using an HP 4500 ICP-MS (Hewlett-Packard, Yokowaga, Japan).
The operating conditions were the same as those outlined
previously (Screnci et al, 1998). At 24h after drug administration,
animals were anaesthetised using 0.9ml of 3mgml
 1 pentobarbi-
tone and exsanguinated. L4, L5 and L6 dorsal root ganglia were
dissected out and prepared for ICP-MS analysis as described
previously (Screnci et al, 1998). Briefly, tissues were left overnight
in a 1ml solution of 70% nitric acid, before digestion for 2h at
901C in a sand bath. On the day of analysis, each sample was made
up to 10ml by addition of milli-Q water and then introduced into
the ICP-MS. Plasma and tissue platinum content was determined
from standards made up in the relevant matrix.
Statistical analysis
The statistical significance of differences between means and
trends was evaluated by 95% confidence intervals (95% CI),
unpaired t-tests, one- or two-way analysis of variance (ANOVA)
and regression analysis using Prism 3.0. software (GraphPad
Software, CA, USA). In each case, a P-value of o0.05 or
nonoverlapping 95% CI was regarded as indicating statistical
significance.
RESULTS
Age-dependent changes in experimental parameters
Significant age-dependent increases in body weight (0.45% day
 1;
Po0.0001; two-way ANOVA), sensory nerve conduction velocity
(0.19% day
 1; Po0.0001; two-way ANOVA), dorsal root ganglion
cell body area (0.8% day
 1; Po0.01; two-way ANOVA) and dorsal
root ganglion nucleolar area (0.3% day
 1; Po0.01; two-way
ANOVA) occurred during the experiment independent of treat-
ment group allocation. There was no significant time-dependent
change in dorsal root ganglion nuclear area.
Paclitaxel and oxaliplatin alone
The effect of paclitaxel on the morphometry of L5 dorsal root
ganglia of rats was studied. A single dose of 10mgkg
 1 of
paclitaxel was well tolerated, but 20mgkg
 1 caused deterioration
in general condition approximately 1 week after dosing necessitat-
ing euthanasia. There was no significant treatment-related change
on L5 dorsal root ganglia cell body or nucleus size after single-dose
paclitaxel. However, nucleolar size was significantly increased
following single doses of 10 and 20mgkg
 1,a t2 4h( Po0.02) and 6
days (Po0.02) (Figures 1 and 2A). Nucleolus size returned to
control values after 14 days. Nucleolus size showed a linear
dependence upon paclitaxel dose at 6h (r
2¼0.54, P¼0.004), 24h
(r
2¼0.79, P¼0.0001) and 6 days (r
2¼0.70, P¼0.0001) after
dosing.
The morphometry of L5 dorsal root ganglia was also studied
after treatment with oxaliplatin. Single doses of oxaliplatin up to
10mgkg
 1 were well tolerated, but 30mgkg
 1 caused deteriora-
tion in general condition within a few days of dosing necessitating
euthanasia. There was no significant change in cell body or nucleus
size but nucleolus size was decreased within a few hours of giving
oxaliplatin (Figures 1 and 2B). Reductions of nucleolus size were
maximal at 24–48h and persisted for at least 2 weeks after dosing.
Nucleolus size showed a nonlinear dependence on oxaliplatin dose
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sat 24h after treatment (r
2¼0.99). The dose curve showed a
maximum reduction of nucleolus size at 53.7% of control (95% CI,
51.9–55.5). The oxaliplatin dose required for half-maximal
reduction in nucleolus size was 4.24mgkg
 1 (95% CI, 3.67–5.02).
To determine the functional significance of these nucleolar
changes, nerve conduction velocity was measured in rats at various
times after treatment with single doses of paclitaxel or oxaliplatin.
A single dose of paclitaxel of 10mgkg
 1 had no effect on sensory
nerve conduction velocity (Figure 3A). However, sensory nerve
conduction velocity was significantly reduced after a single
10mgkg
 1 dose of oxaliplatin (Figure 3B). Nerve conduction
velocity became altered at 14 days after oxaliplatin treatment and
remained reduced until returning to control values at 120 days
postdosing. Thus, sensory nerve conduction velocity became
altered following the onset of oxaliplatin-induced nucleolar
shrinkage, but was unchanged in association with or following
paclitaxel-induced nucleolar enlargement.
Paclitaxel and oxaliplatin in combination
Since oxaliplatin and paclitaxel had opposite effects on dorsal root
ganglion nucleolus size, combination treatment was next studied.
To investigate the early-onset nucleolus changes, a single dose of
paclitaxel (20mgkg
 1) was given 24h before single doses of
oxaliplatin ranging from 1 to 30mgkg
 1. Dorsal root ganglia were
collected 24h after oxaliplatin treatment to determine nucleolus
size. Nucleolus size was significantly increased (Po0.02) after
combination treatment with paclitaxel and oxaliplatin, compared
with oxaliplatin alone, at the 3.3 and 10mgkg
 1 oxaliplatin dose
levels (Figure 4). Nucleolus size was also numerically increased
after combination treatment at the 30mgkg
 1 oxaliplatin dose
A
B
C
20 M
20 M
20 M
Figure 1 Photomicrographs of rat L5 dorsal root ganglia after treatment
with paclitaxel (A), oxaliplatin (B) or control (C). Paclitaxel and oxaliplatin
were given as single i.p. doses of 10mgkg
 1. Dorsal root ganglia were
collected 24h after treatment. Nucleolus size appeared increased and
decreased after treatment with paclitaxel and oxaliplatin, respectively.
Magnification,  630, bar represents 20mm.
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Figure 2 Dorsal root ganglion nucleolus size after treatment with
paclitaxel (A) or oxaliplatin (B). Paclitaxel and oxaliplatin were given as a
single i.p. dose of 0.3mgkg
 1 (J), 1mgkg
 1 (E), 3mgkg
 1 (.),
10mgkg
 1 (’), 20mgkg
 1 (m)o r3 0m gk g
 1 (K) on day 0. Nucleolus
diameter was expressed as the percentage of control. Control values were
determined at each time point. Symbols represent average values (n¼2–
4) and the s.d.
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slevel, although this difference did not reach statistical significance
(P¼0.058). As before, nucleolus size decreased with a nonlinear
dependence on oxaliplatin dose (r
2¼0.99). Based on the
parameters of the fitted curve, the oxaliplatin dose required for
half-maximal reduction in nucleolus size (3.98mgkg
 1 (95% CI,
3.38–4.66)) was not altered by giving paclitaxel (4.32mgkg
 1
(95% CI, 3.53–5.58)). However, the maximal reduction in
nucleolus size was significantly altered by giving paclitaxel with
oxaliplatin (60.1% of control (95% CI, 57.7–62.5)) compared with
giving oxaliplatin alone (55.6% of control (95% CI, 54.0–57.1)).
The effect of single doses of paclitaxel of 10mgkg
 1 in
combination with oxaliplatin was next studied. Paclitaxel
(10mgkg
 1) was given 24h prior to oxaliplatin (10mgkg
 1).
Nucleolus size was measured 24h after oxaliplatin dosing. Sensory
nerve conduction velocity was measured 3 weeks after treatment.
To account for interoccasion variation in experimental parameters
between different batches of animals, data were expressed as
percentage of control. Nucleolus size was increased after paclitaxel
alone (Po0.05), decreased after oxaliplatin alone (Po0.01) but not
significantly altered after giving paclitaxel and oxaliplatin in
combination (Figure 5A). There was a significant reduction in
sensory nerve conduction velocity in the oxaliplatin-alone group
(Po0.05) indicating the presence of functional neurotoxicity
(Figure 5B). However, sensory nerve conduction velocity in the
other treatment groups, given paclitaxel alone or paclitaxel
combined with oxaliplatin, was similar to the control group.
The possibility of a pharmacokinetic interaction being a basis
for the reduction in oxaliplatin toxicity was next investigated.
Paclitaxel (10mgkg
 1), or its drug vehicle, were given 24h before
oxaliplatin (10mgkg
 1). Blood was then collected at various times
over 24h and lumbar dorsal root ganglia were collected 24h after
dosing. The platinum content of dorsal root ganglia and
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Figure 3 Nerve conduction velocity after treatment with paclitaxel (A)
or oxaliplatin (B). Paclitaxel and oxaliplatin were given as single i.p. doses of
10mgkg
 1 (m) on day 0. Controls were given the corresponding drug
vehicle (’) on day 0. Sensory nerve conduction velocity was measured at
various times after treatment. Symbols represent averaged values (n¼20–
25) and the s.e.m. **, Po0.005; *, Po0.05.
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Figure 4 Dorsal root ganglia nucleolus size after oxaliplatin alone (’)o r
oxaliplatin given in combination with paclitaxel (m). Paclitaxel was given as
a single i.p. dose of 20mgkg
 1. Oxaliplatin was given 24h later as single i.p.
doses of 1–30mgkg
 1. Dorsal root ganglia were collected 24h after
oxaliplatin dosing to determine nucleolus size. Symbols represent averaged
values (n¼2–6) and the s.e.m. *, Po0.02.
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Figure 5 Dorsal root ganglion nucleolus size (A) and nerve conduction
velocity (B) after paclitaxel and oxaliplatin given alone or in combination.
Paclitaxel was given as a single i.p. dose of 10mgkg
 1. After 24h later,
oxaliplatin was given as a single i.p. dose of 10mgkg
 1. Drug vehicle was
given to controls at corresponding times. Dorsal root ganglia were
collected for determining nucleolus size at 24h after oxaliplatin dosing.
Sensory nerve conduction velocity was measured 3 weeks after oxaliplatin
dosing. Bars represent the mean and the s.e.m. n¼3–4 for nucleolus size,
n¼23–25 for nerve conduction velocity; *, Po0.05; **, Po0.01.
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sdeproteinised plasma was determined by ICP-MS. The AUC of
unbound plasma oxaliplatin-derived platinum (33.072.39nghl
 1)
was not significantly altered by giving paclitaxel
(42.474.55nghl
 1; P¼0.1). Similarly, the platinum content of
lumbar dorsal root ganglia 24h after oxaliplatin treatment
(1.3070.10ngmg
 1) was not significantly altered by giving
paclitaxel (1.4770.13ngmg
 1; P¼0.33). Thus, under conditions
associated with reduction of oxaliplatin toxicity, there was no
significant reduction in the concentrations of oxaliplatin-derived
platinum in the plasma or dorsal root ganglia.
DISCUSSION
In the present study, the effects of the systemic administration of
paclitaxel were investigated at pharmacologically relevant doses
in vivo. Morphometric analysis of L5 dorsal root ganglia revealed
enlargement of the nucleoli in the cell bodies of sensory neurons
after a single-dose treatment. Time-dependent changes in dorsal
root ganglion morphometric parameters and sensory nerve
conduction velocity were also documented that occurred indepen-
dent of paclitaxel treatment and might have resulted from the
growth of animals during the experiments. Despite the changing
baselines, significant increases in nucleolus size were found in
association with paclitaxel treatment at 24h and 6 days after a
single dose. At 24h after doses of 10 and 20mgkg
 1, averaged
nucleolar diameters increased by 5.6 and 19.6% relative to control,
respectively. Thus, the systemic administration of paclitaxel was
associated with nucleolar enlargement in dorsal root ganglion
neurons after pharmacologically relevant doses in vivo.
The cell bodies of peripheral nerves are known to undergo
nucleolar enlargement, in conjunction with other responses, after
damage to their peripherally directed axons (reviewed in Lieber-
man, 1971). For example, dorsal root ganglion neurons develop an
increase in nucleolar size after crush injuries to the sciatic nerve
(Wells and Vaidya, 1989). Like other antimicrotubule agents,
paclitaxel is known to damage the axons of peripheral nerves
(Cavaletti et al, 1995, 1997; Authier et al, 2000; Mimura et al, 2000).
Direct injection of paclitaxel into peripheral nerves has also been
shown in one previous study to cause nucleolar enlargement in the
corresponding nerve cell bodies (Nennesmo and Reinholt, 1988).
These considerations might suggest that the nucleolar enlargement
demonstrated in the present study is due to a retrograde response
of dorsal root ganglion cell bodies to peripheral axon injury.
However, the effect of paclitaxel on dorsal root ganglion nucleoli in
this study occurred independent of paclitaxel-induced axonal
damage that was detectable by changes in sensory nerve
conduction velocity.
Other mechanisms could therefore be involved in the nucleolar
enlargement caused by paclitaxel. Fluorescent paclitaxel deriva-
tives have been shown to bind avidly to the nucleoli of interphase
cells (Guy et al, 1996; Rao et al, 1998) and binding of nucleolar
proteins by exogenous substances can alter the size and
composition of the nucleolus (Abadia-Molina et al, 1998).
Paclitaxel has also been shown to induce the expression of
numerous genes (Moos and Fitzpatrick, 1998; Fukusaki et al, 2001)
at concentrations possibly achieved under the conditions used in
the present study. Changes in gene expression may be the basis for
paclitaxel effects on nucleolus size since this is the site of
transcription of rDNA genes (Shaw and Jordan, 1995) and
variations in nucleolar dimensions are closely linked to changes
in rRNA synthesis (Goessens, 1984).
Oxaliplatin also altered dorsal root ganglion nucleolus size.
Significant reductions of nucleolus diameter occurred after single
doses of oxaliplatin at a range of doses and time points. The
changes in nucleolus size induced by oxaliplatin were in the
opposite direction compared to those induced by paclitaxel.
Alterations in dorsal root ganglion nucleoli appear to be linked
with the neurotoxicity of platinum-based drugs. For example, we
have previously shown that the neurotoxicity of platinum-based
drugs correlates with the rate of dorsal root ganglion nucleolus
shrinkage during multiple-dose drug treatment (McKeage et al,
2001). Several groups have reported that shrinkage of dorsal root
ganglion nucleoli is associated with cisplatin (Tomiwa et al, 1986;
Muller et al, 1990; Cavaletti et al, 1992; Cece et al, 1995; Stacchiotti
et al, 1995), carboplatin (Cavaletti et al, 1998) and ormaplatin
(Holmes et al, 1998). The change in nucleolus size may come about
by the inhibition of rRNA synthesis, which is a known effect of
platinum-based drugs (Jordan and Carmo-Fonseca, 1998).
Since oxaliplatin and paclitaxel had opposing effects on dorsal
root ganglion nucleolar size, they were also studied in combina-
tion. Prior paclitaxel significantly inhibited the reductions in
nucleolus size and nerve conduction velocity induced by a single
dose of oxaliplatin. The inhibitory effect of paclitaxel was not
explained by a pharmacokinetic interaction. Paclitaxel did not
significantly alter the plasma AUC for unbound oxaliplatin-derived
platinum or the levels of oxaliplatin-derived platinum in dorsal
root ganglia 24h after treatment. In fact, there were nonsignificant
trends towards higher platinum levels in the combination group
that would have been expected to increase rather than reduce
oxaliplatin toxicity. A pharmacodynamic interaction is therefore
likely to have been involved in the paclitaxel inhibition of
oxaliplatin neurotoxicity. Dorsal root ganglion neurons are well
known for regenerating after peripheral nerve injuries (Bradbury
et al, 2000). After peripheral nerve damage, dorsal root ganglia
neurons show augmented recovery from a subsequent and more
central injury (Oblinger and Lasek, 1984; Richardson and Issa,
1984; Chong et al, 1999). In this way, paclitaxel-induced axon
damage may condition dorsal root ganglion neurons into a state of
lower susceptibility to oxaliplatin toxicity without altering its
pharmacokinetics.
In contrast to the present study, clinical trials of paclitaxel and
oxaliplatin in combination have shown frequent and limiting
neurotoxicity (Faivre et al, 1999; Delaloge et al, 2000). However,
the conditions used in these clinical trials were not optimal for
reducing neurotoxicity by this mechanism. For instance, we have
previously shown minimisation of neurotoxicity when taxane
drugs are given before platinum-based drugs but not with the
reverse sequence of drug administration (McKeage et al, 1999). In
two of the clinical trials, oxaliplatin was given before paclitaxel
(Faivre et al, 1999; Liu et al, 2002), a dosing sequence not expected
to show reduced neurotoxicity based on our previous work.
Inhibition of neurotoxicity may also depend upon the kinetics of
the onset of the paclitaxel effect on dorsal root ganglion neuronal
nucleoli. In the present study, nucleolar enlargement was maximal
24h after paclitaxel dosing, and giving paclitaxel 24h before
oxaliplatin inhibited oxaliplatin neurotoxicity. A delay between
giving the two drugs may be required for the development of a cell
body response to paclitaxel-induced axonal damage. In the clinical
trials reported to date, paclitaxel and oxaliplatin were given
sequentially without any dosing interval between giving the drugs
(Faivre et al, 1999; Delaloge et al, 2000; Liu et al, 2002). Further
clinical trials could be envisaged where paclitaxel was given 24h
before oxaliplatin, with neurotoxicity evaluation by symptom
grading and electrophysiology carried out within a few days of the
first treatment (Wilson et al, 2002). If evidence of reduced
neurotoxicity was obtained, clinical trials could investigate
whether minimisation of neurotoxicity is sustained during multi-
ple-dose combination treatment with paclitaxel and oxaliplatin.
In conclusion, the systemic administration of paclitaxel, at
pharmacologically relevant doses, caused nucleolar enlargement in
dorsal root ganglion neurons in vivo. The mechanism of nucleolar
enlargement may involve a response of the dorsal root ganglion
cell body to a peripheral axonal injury. In contrast, oxaliplatin
caused shrinkage of the dorsal root ganglion nucleoli in vivo.I n
combination with oxaliplatin, paclitaxel did not alter the plasma
DRG nucleolar enlargement by paclitaxel
SMF Jamieson et al
1946
British Journal of Cancer (2003) 88(12), 1942–1947 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
spharmacokinetics or dorsal root ganglion accumulation of
oxaliplatin-derived platinum. However, paclitaxel inhibited oxali-
platin-induced dorsal root ganglia nucleolar damage and its
neurotoxicity. The neurotoxicity of platinum–taxane combination
chemotherapy may therefore depend upon opposing drug actions
on the nucleolus of dorsal root ganglion neurons.
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